

PATENT COOPERATION TREATY

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

Date of mailing (day/month/year)
30 May 2001 (30.05.01)

To:

Commissioner
US Department of Commerce
United States Patent and Trademark
Office, PCT
2011 South Clark Place Room
CP2/5C24
Arlington, VA 22202
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

International application No.

PCT/US00/12251

Applicant's or agent's file reference

GM50053

International filing date (day/month/year)

04 May 2000 (04.05.00)

Priority date (day/month/year)

07 May 1999 (07.05.99)

Applicant

BROWN, James, R. et al

1. The designated Office is hereby notified of its election made:

in the demand filed with the International Preliminary Examining Authority on:

08 November 2000 (08.11.00)

in a notice effecting later election filed with the International Bureau on:

2. The election was

was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer

Zakaria EL KHODARY

Telephone No.: (41-22) 338.83.38

US0012251

PATENT COOPERATION TREATY

PCT

04 MAY 2001

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference GM50053	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/US00/12251	International filing date (day/month/year) 04 MAY 2000	Priority date (day/month/year) 07 MAY 1999
International Patent Classification (IPC) or national classification and IPC Please See Supplemental Sheet.		
Applicant SMITHKLINE BEECHAM CORPORATION		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.


2. This REPORT consists of a total of 5 sheets.

This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority. (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 0 sheets.

3. This report contains indications relating to the following items:

- I Basis of the report
- II Priority
- III Non-establishment of report with regard to novelty, inventive step or industrial applicability
- IV Lack of unity of invention
- V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI Certain documents cited
- VII Certain defects in the international application
- VIII Certain observations on the international application

Date of submission of the demand 08 NOVEMBER 2000	Date of completion of this report 16 APRIL 2001
Name and mailing address of the IPEA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer  TEXCHAND SAIDHA Telephone No. (703) 308-0196

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US00/12251

I. Basis of the report1. With regard to the **elements** of the international application:^{*} the international application as originally filed the description:pages 1-39, as originally filed
pages NONE, filed with the demand
pages NONE, filed with the letter of _____ the claims:pages 40-53, as originally filed
pages NONE, as amended (together with any statement) under Article 19
pages NONE, filed with the demand
pages NONE, filed with the letter of _____ the drawings:pages 1-6, as originally filed
pages NONE, filed with the demand
pages NONE, filed with the letter of _____ the sequence listing part of the description:pages 1-6, as originally filed
pages NONE, filed with the demand
pages NONE, filed with the letter of _____2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language _____ which is:

 the language of a translation furnished for the purposes of international search (under Rule 23.1(b)). the language of publication of the international application (under Rule 48.3(b)). the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing: contained in the international application in printed form. filed together with the international application in computer readable form. furnished subsequently to this Authority in written form. furnished subsequently to this Authority in computer readable form. The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished. The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.4. The amendments have resulted in the cancellation of: the description, pages NONE the claims, Nos. NONE the drawings, sheets/fig NONE5. This report has been drawn as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).^{**}^{*} Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).^{**} Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been and will not be examined in respect of:

- the entire international application.
 claims Nos. 13, 15, 17-20

because:

- the said international application, or the said claim Nos. _ relate to the following subject matter which does not require international preliminary examination (*specify*).

- the description, claims or drawings (*indicate particular elements below*) or said claims Nos. _ are so unclear that no meaningful opinion could be formed (*specify*).

- the claims, or said claims Nos. _ are so inadequately supported by the description that no meaningful opinion could be formed.

- no international search report has been established for said claims Nos. 13, 15, 17-20.

2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

- the written form has not been furnished or does not comply with the standard.
 the computer readable form has not been furnished or does not comply with the standard.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US00/12251

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. statement

Novelty (N)

Claims 1-12, 14, 16, 21-42 YES
Claims NONE NO

Inventive Step (IS)

Claims 1-12, 14, 16, 21-42 YES
Claims NONE NO

Industrial Applicability (IA)

Claims 1-12, 14, 16, 21-42 YES
Claims NONE NO

2. citations and explanations (Rule 70.7)

Claims 1-12, 14, 16 and 21-42 meet the criteria set out in PCT Article 33(2)-(4), because the prior art does not teach or fairly suggest the claimed isolated polynucleotide, vector, host cell and method of making the polypeptide, or antagonists that inhibit the polypeptide expression, or the methods associated with the novel polypeptide or inhibitor compounds. O'Connell et al. teach aroA gene of Staphylococcus encoding an EPSP synthase. The claimed Streptococcus pneumoniae DNA sequence encoding the amino acid sequence of SEQ ID NO : 2 having 70 % homology or methods based upon the sequences, is outside the range of teachings of O'Connell et al.

Claims 1-12, 14, 16 and 21-42 meet the criteria set out in PCT Article 33(4), because the subject matter claimed can be made or used in industry.

----- NEW CITATIONS -----

O'CONNELL et al. Sequence and Mapping of the aroA gene of Staphylococcus aureus 8325-4. Journal of General Microbiology. 1993, Vol. 139, pages 1449-1460, see the entire document.

MAJUMDER et al. 5-Enolpyruvylshikimate-3-phosphate synthase of Bacillus subtilis is an allosteric enzyme. Eur. J. Biochem. 1995, Vol. 229, pages 99-106, see the entire document.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US00/12251

Supplemental Box

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: Boxes I - VIII

Sheet 10

CLASSIFICATION:

The International Patent Classification (IPC) and/or the National classification are as listed below:

IPC(7): C07H 21/04; C12P 21/06; C12N 1/20, 15/00 and US Cl.: 536/23.1, 23.7; 435/69.1, 69.2, 252.3, 320.1

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C07H 21/04, C12P 21/06, C12N 1/20, 15/00		A1	(11) International Publication Number: WO 00/68243
(21) International Application Number: PCT/US00/12251		(43) International Publication Date: 16 November 2000 (16.11.00)	
(22) International Filing Date: 4 May 2000 (04.05.00)		(74) Agents: GHMMI Edward, R. et al.; SmithKline Beecham Corporation, Corporate Intellectual Property, UW2220, 700 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406-0939 (US).	
(30) Priority Data: 60/133,070 7 May 1999 (07.05.99) US		(81) Designated States: JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(71) Applicants (<i>for all designated States except US</i>): SMITHKLINE BEECHAM CORPORATION [US/US]; One Franklin Plaza, Philadelphia, PA 19103 (US). SMITHKLINE BEECHAM PLC [GB/GB]; New Horizons Court, Great West Road, Brentford, Middlesex TW8 9EP (GB).			
(72) Inventors; and			
(75) Inventors/Applicants (<i>for US only</i>): BROWN, James, R. [CA/US]; 9 Robins Lane, Berwyn, PA 19312 (US). CHALKER, Alison, F. [GB/US]; 137 Havard Drive, College Woods, Trappe, PA 19426 (US). KATZ, Lisa, K. [US/US]; 6 East Park Road, Newtown, PA 18940 (US). MAZZULLA, Marie, Jean [US/US]; 2029 Greenes Way Circle, Collegeville, PA 19426 (US). PAYNE, David, J. [GB/US]; 618 Waterfall Way, Phoenixville, PA 19460 (US). TRAINI, Christopher, M. [US/US]; 50 Potter Court, Media, PA 19063 (US). DU, Wengsheng [CN/US]; 406 Meadowview Lane, Mont Clare, PA 19453 (US).			
(54) Title: METHODS USING MECHANISMS OF ACTION OF AROA			
(57) Abstract			
The invention provides aroA polypeptides and DNA (RNA) encoding aroA polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing aroA polypeptides to screen for antibacterial compounds.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00 12251

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) :C07H 21/04; C12P 21/06; C12N 1/20, 15/00
US CL :536/23.1, 23.7; 435/69.1, 69.2, 252.3, 320.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/23.1, 23.7; 435/69.1, 69.2, 252.3, 320.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

West and STN files : medline, caplus, uspatfull, biosis, scisearch - search terms : aroA gene[†] and streptococcus pneumoniae.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	45,883,239A (BROWN ET AL.) 16 March 1999 (16.3.1999), see entire document, especially the abstract.	1-12, 14, 16, 21-42

<input type="checkbox"/>	Further documents are listed in the continuation of Box C.	<input type="checkbox"/>	See patent family annex.
A	Special categories of cited documents	*T*	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory made known the invention
E	document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
L	earlier document published on or after the international filing date	*Y*	document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
O	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z*	document member of the same patent family
P	document referring to an oral disclosure, use, exhibition or other means		
	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search	Date of mailing of the international search report
25 JULY 2000	10 AUG 2000
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer TEKCHNAI SARDHA Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORTInternational application No.
PCT/US00/12251**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
1-12, 14, 16 & 21-42
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT US00 12251

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claim(s)1-12, drawn to polynucleotide encoding aroA polypeptide, vector host cells and method of making the polypeptide.

Group II, claim(s)13, drawn to antibody against the polypeptide of claim 11.

Group III, claim(s)14, 16 & 21-42, drawn to antagonists and method of use.

Group IV, claim(s) 15 drawn to a method of treatment using aroA.

Group V, claim(s) 17, drawn to Process of diagnosing a disease.

Group VI, claim(s) 18, drawn to polypeptide inhibitors

Group VII, claims 19-20, drawn to a method of inducing an immunological response.

The inventions listed as Groups I-VII do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The Polynucleotide of Group I and the antibody of Group II do not require each other for their practice, have separate utilities, such as the polynucleotide of Group I can be used for recombinant expression of the aroA polypeptide versus the use of antibody to detect proteins. Group I has a special technical feature of nucleotide sequence encoding aroA which Groups II-VII do not share; Group II has the special technical feature of an antibody which Group I and III-VII do not share; Group III has the special technical feature of an antagonist, which Groups I-II and Groups IV-VII do not share; Group IV has the special technical feature of an a treatment based upon aroA polypeptide, which Groups I-III and Groups V-VII do not share; Group V has the special technical feature of a process for diagnosis of disease based upon expression of protein, which Groups I-IV and Groups VI-VII do not share; Group VI has the special technical feature of an of a method for identifying compounds which inhibit polypeptide activity, which Groups I-V and Groups VII do not share; Group VII has the special technical feature of a method for inducing an immunological response, which Groups I-VI do not share.

SEQUENCE LISTING

<110> SMITHKLINE BEECHAM CORPORATION
SMITHKLINE BEECHAM plc

<120> METHODS USING MECHANISMS OF ACTION OF
AroA

<130> GM50053

<140> TO BE ASSIGNED
<141> 2000-05-04

<150> US 60/133,070
<151> 1999-05-07

<160> 4

<170> FastSEQ for Windows Version 3.0

<210> 1
<211> 1284
<212> DNA
<213> Streptococcus pneumoniae

<400> 1

atgaaaactaa	aaacaaacat	tcgcattta	catggtatta	tccgcgtccc	aggtgacaag	60
tctatcagcc	accgttccat	tatcttgga	agtttggctg	agggtgagac	caaggtttat	120
gatattctgc	gaggtgaaga	cgttcttcg	accatgcagg	ttttcgtga	ccttgggttt	180
gaaattgagg	ataaagatgg	ggttattacc	gttcaagggtg	taggcattgc	tggctaaaa	240
gcccgc当地	atgcccttaa	tatggaaat	tctggcacct	cgattcgctt	gatttcaggt	300
gtccttgc当地	gtgcagattt	cgaagttagag	atgtttggag	atgatagtct	ttccaaacgt	360
cctatggacc	gtgtgaccct	tccactgaaa	aaaatggcg	tcagcatctc	agggcaaact	420
gaacgagact	tgcctccct	tcgctaaaa	gggacgaaaa	acctaagacc	tattcattat	480
gagttgccaa	ttgcctctgc	ccaagtcaag	tcagccttga	tgtttgcagc	cttacaagct	540
aagggggagt	cagttattat	cggaaaaagag	tacacccgta	atcataactga	agatatagttg	600
caacaatttg	gtggtcattt	aagtgtggat	ggtaagaaaa	tcacagtcca	agggccacaa	660

aaattgacag gacagaagg tgcgtacca ggagatattt ccagtgcagc ctttggtta 720
 gtcgcagggtt tgattgtcc aaattctcg ttagtgcgtc agaatgtggg gataaacgaa 780
 actcgccaccg gtattattga tgcattcg tccatgggtg gaaaattgga aataactgaa 840
 atcgatccag tcgctaaatc tgcaaccttg attgttgagt ctctgactt gaaaggaaca 900
 gagatttggc ggcgtttgtat tccacgtttg attgtatgaat tgcctattat tgcctactt 960
 ggcacccaag cccaaagggtgt aacagttatc aaggatgctg aggagctcaa ggtcaaggaa 1020
 acagaccgta ttcatgggtgt ggcagacgcc ttaaatagta tgggagcaga tattactcct 1080
 acggcagatg ggtatgattt caaaggaaaaa tcagctcttc acgggtgctag agtcaatacg 1140
 tttggtgacc accgtatcg catgtgaca gctatgcag ccctatttgt tgcagatgga 1200
 gaggtggagc ttgaccgtgc agaagccatc aataccagct atcctagttt ctttgatgat 1260
 ttggagagct tgattcatgg ctaa 1284

<210> 2

<211> 427

<212> PRT

<213> Streptococcus pneumoniae

<400> 2

Met Lys Leu Lys Thr Asn Ile Arg His Leu His Gly Ile Ile Arg Val			
1	5	10	15
Pro Gly Asp Lys Ser Ile Ser His Arg Ser Ile Ile Phe Gly Ser Leu			
20	25		30
Ala Glu Gly Glu Thr Lys Val Tyr Asp Ile Leu Arg Gly Glu Asp Val			
35	40		45
Leu Ser Thr Met Gln Val Phe Arg Asp Leu Gly Val Glu Ile Glu Asp			
50	55		60
Lys Asp Gly Val Ile Thr Val Gln Gly Val Gly Met Ala Gly Leu Lys			
65	70	75	80
Ala Pro Gln Asn Ala Leu Asn Met Gly Asn Ser Gly Thr Ser Ile Arg			
85	90		95
Leu Ile Ser Gly Val Leu Ala Gly Ala Asp Phe Glu Val Glu Met Phe			
100	105		110
Gly Asp Asp Ser Leu Ser Lys Arg Pro Met Asp Arg Val Thr Leu Pro			
115	120		125
Leu Lys Lys Met Gly Val Ser Ile Ser Gly Gln Thr Glu Arg Asp Leu			
130	135		140
Pro Pro Leu Arg Leu Lys Gly Thr Lys Asn Leu Arg Pro Ile His Tyr			
145	150	155	160

Glu Leu Pro Ile Ala Ser Ala Gln Val Lys Ser Ala Leu Met Phe Ala
165 170 175
Ala Leu Gln Ala Lys Gly Glu Ser Val Ile Ile Glu Lys Glu Tyr Thr
180 185 190
Arg Asn His Thr Glu Asp Met Leu Gln Gln Phe Gly Gly His Leu Ser
195 200 205
Val Asp Gly Lys Lys Ile Thr Val Gln Gly Pro Gln Lys Leu Thr Gly
210 215 220
Gln Lys Val Val Val Pro Gly Asp Ile Ser Ser Ala Ala Phe Trp Leu
225 230 235 240
Val Ala Gly Leu Ile Ala Pro Asn Ser Arg Leu Val Leu Gln Asn Val
245 250 255
Gly Ile Asn Glu Thr Arg Thr Gly Ile Ile Asp Val Ile Arg Ala Met
260 265 270
Gly Gly Lys Leu Glu Ile Thr Glu Ile Asp Pro Val Ala Lys Ser Ala
275 280 285
Thr Leu Ile Val Glu Ser Ser Asp Leu Lys Gly Thr Glu Ile Cys Gly
290 295 300
Ala Leu Ile Pro Arg Leu Ile Asp Glu Leu Pro Ile Ile Ala Leu Leu
305 310 315 320
Ala Thr Gln Ala Gln Gly Val Thr Val Ile Lys Asp Ala Glu Glu Leu
325 330 335
Lys Val Lys Glu Thr Asp Arg Ile Gln Val Val Ala Asp Ala Leu Asn
340 345 350
Ser Met Gly Ala Asp Ile Thr Pro Thr Ala Asp Gly Met Ile Ile Lys
355 360 365
Gly Lys Ser Ala Leu His Gly Ala Arg Val Asn Thr Phe Gly Asp His
370 375 380
Arg Ile Gly Met Met Thr Ala Ile Ala Ala Leu Leu Val Ala Asp Gly
385 390 395 400
Glu Val Glu Leu Asp Arg Ala Glu Ala Ile Asn Thr Ser Tyr Pro Ser
405 410 415
Phe Phe Asp Asp Leu Glu Ser Leu Ile His Gly
420 425

<210> 3

<211> 1245

<212> DNA

<213> *Streptococcus pneumoniae*

<220>

<221> unsure

<222> (482) (483) (484) (485) (486) (487) (488) (489) (490) (491) (492)
(493) (494) (495) (496) (497) (498) (499)

<400> 3

agttgtatcg tcccaggtga caagtctatc agccaccgtt ccattatctt tggaagtttg	60
gctgagggtg agaccaaggt ttatgatatt ctgcgaggtg aacacgttct ttcgaccatg	120
caggtttttc gtgacccttgg tgttgaatt gaggataaag atggggttat taccgttcaa	180
ggtgttaggsa tggctggcctt aaaagcgccg caaaatgccc ttaatatggg aaattctggc	240
acctcgatcc gcctgatttc aggtgtcctt gctggcgtcag atttcgaagt agagatgttt	300
ggagatgata gtcttccaa acgtcctatg gaccgtgtga cccttccact gaaaaaaaaatg	360
ggcgtcagca tctcagggca aactgaacga gacttgcctc cccttcgcctt taaaagggac	420
gaaaaaccta agaccttattc attatgagtt gccaattgcc tctgcccag tcaagtccgc	480
cnnnnnnnnnnnnnnnn taagggggag tcagttatta tcgaaaaaga gtacacccgt	540
aatcatactg aagatatgtt gcaacaattt ggtggtcatt taagtgtgga tggtaagaaa	600
atcacagtcc aaggcccaca aaaattgaca ggacagaagg tggtcgtacc aggagatatt	660
tccagtgcag cctttgggtt agtgcgcaggt ttgattgctc caaattctcg tctagtgcgt	720
cagaatgtgg ggataaacga aactcgcacc ggtattattt atgtcattcg tgccatgggt	780
ggaaaattgg aaataactga aatcgatcca gtcgctaaat ctgcaacattt gattgtttag	840
tcttctgact tgaaaggaac agagattttt ggcgtttga ttccacgttt gattgtatgaa	900
ttgccttatta ttgcctact tgcgacccaa gcccaaggtg taacagttat caaggatgct	960
gaggagctca aggtcaagga aacagaccgt attcaggttg tggcagacgc cttaaatagt	1020
atgggagcag atattactcc tacggcagat gggatgatta tcaaaggaaa atcagcttcc	1080
cacggtgcta gagtcaatac gtttggtgac caccgtatcg gcatgatgac agctatcgca	1140
gccctattgg ttgcagatgg agaggtggag cttgaccgtg cagaagccat caataccagc	1200
tatecttagtt tctttgatga tttggagagc ttgattcatg gctaa	1245

<210> 4

<211> 415

<212> PRT

<213> *Streptococcus pneumoniae*

<220>

<221> unsure

<222> (149) (161) (162) (163) (164) (165) (166) (167) (168)

<400> 4

Ser Leu Ile Val Pro Gly Asp Lys Ser Ile Ser His Arg Ser Ile Ile
1 5 10 15
Phe Gly Ser Leu Ala Glu Gly Glu Thr Lys Val Tyr Asp Ile Leu Arg
20 25 30
Gly Glu His Val Leu Ser Thr Met Gln Val Phe Arg Asp Leu Gly Val
35 40 45
Glu Ile Glu Asp Lys Asp Gly Val Ile Thr Val Gln Gly Val Gly Met
50 55 60
Ala Gly Leu Lys Ala Pro Gln Asn Ala Leu Asn Met Gly Asn Ser Gly
65 70 75 80
Thr Ser Ile Arg Leu Ile Ser Gly Val Leu Ala Gly Ala Asp Phe Glu
85 90 95
Val Glu Met Phe Gly Asp Asp Ser Leu Ser Lys Arg Pro Met Asp Arg
100 105 110
Val Thr Leu Pro Leu Lys Lys Met Gly Val Ser Ile Ser Gly Gln Thr
115 120 125
Glu Arg Asp Leu Pro Pro Leu Arg Phe Lys Arg Asp Glu Lys Pro Lys
130 135 140
Thr Tyr Ser Leu Xaa Val Ala Asn Cys Leu Cys Pro Ser Gln Val Ser
145 150 155 160
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Lys Gly Glu Ser Val Ile Ile Glu
165 170 175
Lys Glu Tyr Thr Arg Asn His Thr Glu Asp Met Leu Gln Gln Phe Gly
180 185 190
Gly His Leu Ser Val Asp Gly Lys Lys Ile Thr Val Gln Gly Pro Gln
195 200 205
Lys Leu Thr Gly Gln Lys Val Val Val Pro Gly Asp Ile Ser Ser Ala
210 215 220
Ala Phe Trp Leu Val Ala Gly Leu Ile Ala Pro Asn Ser Arg Leu Val
225 230 235 240
Leu Gln Asn Val Gly Ile Asn Glu Thr Arg Thr Gly Ile Ile Asp Val
245 250 255
Ile Arg Ala Met Gly Gly Lys Leu Glu Ile Thr Glu Ile Asp Pro Val
260 265 270
Ala Lys Ser Ala Thr Leu Ile Val Glu Ser Ser Asp Leu Lys Gly Thr
275 280 285
Glu Ile Cys Gly Ala Leu Ile Pro Arg Leu Ile Asp Glu Leu Pro Ile
290 295 300

Ile Ala Leu Leu Ala Thr Gln Ala Gln Gly Val Thr Val Ile Lys Asp
305 310 315 320
Ala Glu Glu Leu Lys Val Lys Glu Thr Asp Arg Ile Gln Val Val Ala
325 330 335
Asp Ala Leu Asn Ser Met Gly Ala Asp Ile Thr Pro Thr Ala Asp Gly
340 345 350
Met Ile Ile Lys Gly Lys Ser Ala Leu His Gly Ala Arg Val Asn Thr
355 360 365
Phe Gly Asp His Arg Ile Gly Met Met Thr Ala Ile Ala Ala Leu Leu
370 375 380
Val Ala Asp Gly Glu Val Glu Leu Asp Arg Ala Glu Ala Ile Asn Thr
385 390 395 400
Ser Tyr Pro Ser Phe Phe Asp Asp Leu Glu Ser Leu Ile His Gly
405 410 415